CEO Succession Planning for Clinical-Stage Companies
Most clinical-stage biopharma boards treat CEO succession planning as a problem for later. There is always a more pressing reason to defer it: a trial readout is approaching, a financing round is consuming the agenda, the current CEO is performing well and the conversation feels premature, or the board simply has not prioritized allocating time to something with no immediate deadline.
The problem with this logic is that succession events are rarely scheduled. A CEO departure — whether voluntary, health-related, or board-initiated — rarely announces itself with adequate preparation time. The companies that navigate these transitions well are the ones that treated succession as an ongoing governance obligation rather than a crisis response. The ones that struggle are the ones that discover, at the moment of need, that they have no plan, no pipeline, and no shared understanding of what the next leader needs to look like.
In clinical-stage biopharma, the cost of a poorly managed CEO transition is not abstract. It lands directly on the timeline of the science, the confidence of investors, the stability of the team, and the credibility of the company with its regulatory and partnership counterparties. Getting succession planning right — and getting it right early — is one of the highest-value governance investments a board can make.
Why Succession Planning Feels Premature — and Why That Feeling Is Wrong
There are a set of conditions that make succession planning feel unnecessary, and they are almost perfectly correlated with the conditions under which it is most needed.
A company with a strong founder-CEO, a clear scientific mission, and an early-stage pipeline feels like a poor candidate for succession planning because the leader is irreplaceable and the organization would not survive without them. This is precisely the situation in which the absence of a plan creates the most risk. A company built entirely around one person's scientific vision, industry relationships, and institutional knowledge is acutely vulnerable to any disruption in that person's capacity to lead — and the transition, if it comes, will be managed in conditions of maximum organizational fragility.
A company in the middle of a clinical program feels like a poor candidate for succession planning because there are more important things to do. But clinical programs create defined milestones that are themselves succession trigger points. A CEO who has built the company through early discovery and has strengths in scientific storytelling and investor relations may not be the right leader for the commercial preparation phase. Boards that have not thought through this question before the milestone arrives discover it in the middle of the milestone — the worst possible moment for a leadership conversation.
A board that has complete confidence in the current CEO's performance and tenure feels like it does not need a succession plan because the plan is implicitly to continue with the current leader. But succession planning is not a vote of no confidence. It is a board's acknowledgment that all leadership arrangements are contingent, that the company's interests are not identical to any individual's continued tenure, and that preparation for transition is a fiduciary obligation independent of any expectation that transition is imminent.
The Two Problems Succession Planning Must Solve
A credible succession plan addresses two distinct problems that are often conflated but require different approaches.
The first is emergency succession: what happens if the CEO is unable to continue in the role without warning. This scenario — whether driven by health, personal circumstances, or a sudden board-initiated departure — requires an immediate answer to the question of who leads the company tomorrow. The emergency succession plan is not a search process; it is a designation. There needs to be a named individual — inside the company or, in smaller organizations, potentially an identified board member — who can assume operational leadership on an interim basis while a deliberate search proceeds.
The second is planned succession: the proactive identification and development of the next CEO, aligned with the company's anticipated evolution. This is a longer-horizon process that involves understanding what leadership profile the company will need at its next stage, assessing whether that profile exists inside the current organization or will need to be recruited, and — where internal candidates exist — actively developing them over time in ways that build their readiness.
Most boards, when they do succession planning at all, focus almost entirely on emergency succession and neglect planned succession. The result is a company that knows who would answer the phone on day one but has no strategy for building or attracting the leadership it will actually need over the next three to five years.
Defining the Leadership Profile — Before You Need It
The foundation of any succession process is clarity about what the next CEO needs to be able to do. This sounds obvious, but it requires a level of specificity that most boards do not reach until they are in the middle of an actual search — when it is too late for clarity to be fully useful.
The leadership profile for a CEO of a clinical-stage biopharma company is not generic. It is shaped by the company's specific assets, stage, therapeutic area, regulatory situation, and strategic path. A company that is eighteen months from a Phase III readout and preparing for potential commercialization discussions needs a different kind of CEO than a company that is entering Phase I with a broad platform and a long horizon to the first meaningful data. A company whose primary near-term goal is a licensing exit to a major pharma partner needs different leadership than one that is preparing to go public.
The board should answer a set of specific questions when defining the profile: What are the two or three most important things the next CEO must accomplish in the first three years? What relationships — regulatory, commercial, investor, scientific — are most critical to the company's success, and does the next leader need to bring those relationships or build them? Is the company's primary challenge scientific, operational, financial, or commercial — and does the candidate profile reflect that priority? What has the current CEO done exceptionally well, and is that something the next leader needs to match, or an area where different capabilities are acceptable?
This exercise is valuable independent of any succession timeline because it forces the board to articulate a strategic view of where the company is going and what it will need to get there. Boards that have done this work consistently make better CEO decisions — both in succession contexts and in evaluating the performance of the current leader.
Internal Candidates: Development, Not Just Identification
In early-stage biopharma companies, internal succession is often either obvious or impossible. A company of fifteen people may have a clear number two — a Chief Scientific Officer or Chief Operating Officer who is deeply embedded in the organization and could step into the CEO role — or it may have no internal candidate at all.
Where internal candidates exist, the board's obligation is not merely to identify them but to actively develop their readiness. This means giving them genuine leadership experience — not simulated exposure, but real responsibility for outcomes that matter. It means ensuring they have visibility with the board directly, not only filtered through the CEO. It means providing candid feedback about where they are strong and where they have developmental gaps relative to the CEO profile the company needs.
It also means having an honest conversation, at the appropriate time, about whether an internal candidate's interest and ambition match the board's assessment of their potential. A COO who is an exceptional operator but has no interest in the external-facing dimensions of the CEO role — investor relations, partnership development, regulatory strategy — is not a strong internal succession candidate regardless of their capabilities in their current function.
Where no internal candidate exists — which is common in founder-led scientific startups — the board should be explicit about this and plan accordingly. An emergency succession plan that designates a board member as interim leader is a reasonable bridge, but it is not a sustainable governance arrangement, and the board should have a clear sense of how quickly it could run an external search and what the priority criteria would be.
Managing the Founder-CEO Dimension
Succession planning in founder-led companies carries a specific complication that deserves direct treatment: the founder-CEO's own relationship to the process.
Founders frequently experience succession planning as a challenge to their authority or a signal of diminished board confidence — even when neither is true. This response is understandable. The company is often an extension of the founder's scientific vision and personal identity. The suggestion that someone else might eventually lead it can feel like a referendum on whether the founder is adequate for the role they have defined.
Boards that handle this well are explicit and consistent in framing succession planning as a governance obligation that applies to every leadership-dependent organization, not a judgment about the current leader's performance. They involve the founder-CEO in the process — not as the decision-maker, but as an important input into defining the leadership profile and identifying internal candidates — in ways that acknowledge their institutional knowledge while preserving the board's authority over the ultimate decision.
They also have the harder conversation, when appropriate, about stage transitions. Many founder-CEOs are ideal leaders for the phase of company development in which they built the organization and may not be the right leaders for the next phase. This is not a criticism — it is a structural reality of how scientific startups evolve. A founder who has the self-awareness to recognize this and work constructively with the board on a transition plan creates enormous value for the company. A board that identifies the mismatch but defers the conversation to avoid conflict creates risk that tends to surface at the worst possible moment.
Process and Cadence
A succession planning process that is functional requires a minimum level of structural regularity. It cannot be a one-time exercise, and it cannot happen only when succession feels imminent.
The board — typically through the compensation or governance committee, or a designated ad hoc subgroup — should review the succession plan at least annually. The review should address whether the emergency succession designation is still appropriate, whether the internal candidate landscape has changed, whether the leadership profile remains accurately calibrated to the company's strategic trajectory, and whether the development activities being provided to internal candidates are working.
The CEO should be involved in this review, transparently, as a collaborator. The board's succession conversation should not happen behind the CEO's back — except in situations where board-initiated departure of the current CEO is being considered, in which case different rules apply.
The results of the annual review should be documented — not in detail that creates legal or operational risk if the document were ever to become external, but sufficiently to preserve institutional memory and ensure that a new board member can quickly understand where the succession conversation stands.
When Succession Becomes Urgent
Despite best efforts, many biopharma boards encounter succession as a crisis rather than a planned transition. The CEO announces an unexpected departure, a health event removes them from the role, or the board reaches a conclusion that leadership change is necessary before any succession infrastructure is in place.
In these situations, the quality of the board's prior governance work determines how gracefully the crisis can be navigated. A board that has discussed the leadership profile, even informally, can move faster to the external search because the criteria conversation has already happened. A board that has identified even a rough internal bridge candidate can stabilize operations while the search proceeds. A board that has relationships with executive search firms in the biopharma space can initiate the process without a standing-start delay.
None of this requires a perfect, fully articulated succession plan. It requires a board that has taken the question seriously enough to have done some of the foundational thinking — and that recognition is itself a reason to begin the process now, regardless of where the company is in its development or how confident the board is in the current CEO.
The time to build the infrastructure for a leadership transition is long before you need it. That has always been true. In clinical-stage biopharma, where the stakes of a badly managed transition reach all the way to the patients at the end of the pipeline, it is especially true.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on leadership structure and governance across clinical-stage life sciences companies.